<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment protocols for multiple myeloma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment protocols for multiple myeloma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment protocols for multiple myeloma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tim Brenner, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shrina Duggal, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jim Natale, PharmD, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            S Vincent Rajkumar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4993546">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with multiple myeloma.
         <strong>
          This is
         </strong>
         <strong>
          not an exhaustive list
         </strong>
         ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with multiple myeloma. Additional regimens may be added over time, particularly as treatment for multiple myeloma evolves.
        </p>
        <p>
         This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with multiple myeloma. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">
          "Multiple myeloma: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6650.html" rel="external">
          "Multiple myeloma: Management in resource-limited settings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">
          "Multiple myeloma: Initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">
          "Multiple myeloma: Treatment of first or second relapse"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
        </p>
        <p class="headingAnchor" id="H4993660">
         <span class="h1">
          REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H936049102">
         <span class="h2">
          Bortezomib (Velcade) plus cyclophosphamide and dexamethasone (VCD or CyBorD)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3011474703">
         <span class="h2">
          Bortezomib (Velcade) plus lenalidomide (Revlimid) and dexamethasone (VRd)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef91054" href="/z/d/graphic/91054.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2028826083">
         <span class="h2">
          Bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H301817861">
         <span class="h2">
          Ixazomib, lenalidomide, and dexamethasone (IRd)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef106536" href="/z/d/graphic/106536.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2072686382">
         <span class="h2">
          Daratumumab, lenalidomide, and dexamethasone (DRd)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef119710" href="/z/d/graphic/119710.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="headingAnchor" id="H936049152">
         <span class="h2">
          Lenalidomide (Revlimid) plus dexamethasone (Rd)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef56451" href="/z/d/graphic/56451.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1604609787">
         <span class="h2">
          Melphalan, prednisone, and thalidomide (MPT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef53179" href="/z/d/graphic/53179.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2067995886">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 85687 Version 24.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
